MVIR Stock Overview
A pharmaceutical company, focuses on the development and commercialization of treatments for cancer in Nordic region, rest of Europe, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Medivir AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 2.71 |
| 52 Week High | SEK 5.75 |
| 52 Week Low | SEK 2.33 |
| Beta | -0.23 |
| 11 Month Change | -7.51% |
| 3 Month Change | -12.86% |
| 1 Year Change | -34.53% |
| 33 Year Change | -75.00% |
| 5 Year Change | -87.57% |
| Change since IPO | -97.96% |
Recent News & Updates
Shareholder Returns
| MVIR | SE Biotechs | SE Market | |
|---|---|---|---|
| 7D | 0.4% | -0.4% | 0.1% |
| 1Y | -34.5% | 15.1% | 11.8% |
Return vs Industry: MVIR underperformed the Swedish Biotechs industry which returned 15.1% over the past year.
Return vs Market: MVIR underperformed the Swedish Market which returned 11.8% over the past year.
Price Volatility
| MVIR volatility | |
|---|---|
| MVIR Average Weekly Movement | 8.2% |
| Biotechs Industry Average Movement | 9.3% |
| Market Average Movement | 5.5% |
| 10% most volatile stocks in SE Market | 11.2% |
| 10% least volatile stocks in SE Market | 3.3% |
Stable Share Price: MVIR's share price has been volatile over the past 3 months compared to the Swedish market.
Volatility Over Time: MVIR's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of Swedish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1987 | 10 | Jens Lindberg | www.medivir.com |
Medivir AB (publ), a pharmaceutical company, focuses on the development and commercialization of treatments for cancer in Nordic region, rest of Europe, and internationally. The company markets Xerclear for the treatment of labial herpes under the Zoviduo name. It is also developing Remetinostat for treating MF cutaneous T-cell lymphoma and basal cell carcinoma, as well as squamous cell carcinoma.
Medivir AB (publ) Fundamentals Summary
| MVIR fundamental statistics | |
|---|---|
| Market cap | SEK 303.97m |
| Earnings (TTM) | -SEK 116.92m |
| Revenue (TTM) | SEK 7.03m |
43.2x
P/S Ratio-2.6x
P/E RatioIs MVIR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MVIR income statement (TTM) | |
|---|---|
| Revenue | SEK 7.03m |
| Cost of Revenue | SEK 97.07m |
| Gross Profit | -SEK 90.03m |
| Other Expenses | SEK 26.89m |
| Earnings | -SEK 116.92m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 18, 2025
| Earnings per share (EPS) | -1.04 |
| Gross Margin | -1,280.14% |
| Net Profit Margin | -1,662.48% |
| Debt/Equity Ratio | 0% |
How did MVIR perform over the long term?
See historical performance and comparison